Shares of Kymera Therapeutics (KYMR) are up 10% at $35.09 afterhours after the company announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi (SNY) has informed Kymera that it intends to expand the ongoing Hidradenitis Suppurativa HS and Atopic Dermatitis AD Phase 2 trials to more rapidly progress towards pivotal studies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics Advances with Sanofi in Phase 2 Trials
- Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
- Kymera Therapeutics Shareholders Approve Key Governance Proposals
- Kymera Therapeutics presents clinical data from Phase 1 trial of KT-333
- Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting